Plus, news about Ventyx Biosciences, CEPI, Evolus, Recursion and Sensorion:
Lexeo Therapeutics raises $95M: The financing is nearly the same size as the gene therapy maker’s $100 million IPO four months ago. The new money from Novo Holdings and other investors is expected to give the clinical-stage biotech runway into 2027. — Kyle LaHucik
Nurix Therapeutics gets FDA go-ahead to continue trial: The regulator lifted its partial hold on Nurix’s Phase Ia/Ib clinical trial investigating NX-2127 to treat B-cell malignancies. The FDA halted the trial in November after the company said it wanted to change the manufacturing process for the drug. NX-2127 works by degrading BTK and IMiD neosubstrates. — Anna Brown
Ventyx Biosciences’ stock sinks on pipeline reorganization: The San Diego startup announced plans to shift focus to two NLRP3 inhibitor programs and partner out a third program, VTX002. Last October, VTX002 succeeded in a Phase II study in ulcerative colitis but analysts wondered whether it could compete with other programs. The reorganization follows a $100 million PIPE announced on Thursday. Ventyx shares $VTYX fell about 20% on Monday. — Max Gelman
CEPI raises $57 million for Covid-19 challenge trials: The studies will examine the effectiveness of nasal and inhaled vaccines in preventing Covid-19. Researchers from Imperial College London will lead the five-year international project. — Max Gelman
Evolus prices $50M offering: The California medical aesthetics company expects to raise the money to grow its neurotoxin Jeuveau business and its line of dermal fillers. — Kyle LaHucik
Recursion opens a London office: The Salt Lake City biotech and its subsidiary Valence Lab are launching in London, with plans to open a new office in King’s Cross in June. The company also appointed Michael Bronstein, an artificial intelligence professor at the University of Oxford, as a scientific advisor. — Anna Brown
Sensorion’s hearing preservation drug reaches proof of concept: The biotech’s SENS-401 met the primary endpoint in a Phase IIa test of 28 patients who underwent a cochlear implant. The study has now finished, and complete data are set to be published in the third quarter. SENS-401 is also in a Phase II trial for the prevention of cisplatin-induced ototoxicity. — Ayisha Sharma
https://endpts.com/lexeo-brings-in-95m-fda-lifts-hold-on-nurix-cancer-trial/
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Navega Therapeutics Receives $4 Million CIRM Grant to Advance Epigenetic Gene Therapy for Chronic Pain
SAN DIEGO, CA – February 4, 2025 – Navega Therapeutics, a pioneering biotechnology company developing cutting-edge epigenetic gene therapies, today announced a significant milestone with the receipt of a $4 million Translational Science grant from the California...
Akribion Therapeutics Secures €8 Million in Seed Financing to Advance Novel RNA-Guided Cell Depletion Technology
ZWINGENBERG, Germany, February 4, 2025 – Akribion Therapeutics, a biotechnology company pioneering a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announced the closing of an €8 million Seed financing round. The round was led by...
UF-Kure19 CAR-T Cell Therapy Demonstrates High CR Rates, Low Toxicity in R/R NHL
Treatment with UF-Kure19, a rapidly manufactured CAR T-cell therapy, led to complete responses (CR) and low toxicity in patients with relapsed/refractory non-Hodgkin lymphoma, according to data from a single-arm, mult-center phase 1 study (NCT05400109) presented at...
Opinion: Companies Vie to Develop a Hunter Syndrome Therapy That Reaches the Brain
Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio—have products in the pipeline that could improve treatment options for this rare disease. Hunter syndrome is a rare, X‐linked disease caused by a deficiency of the lysosomal enzyme...
Related Services

Plasmids GMP Services

AAV GMP Services
